Chang LS, Hassan S, Chasse J, Stern G, et al. Safety of a remote disease management program to improve sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists prescribing in type 2 diabetes with elevated cardiovascular or kidney risk. Am Heart J 2026 Jan 27:107359. doi: 10.1016/j.ahj.2026.107359.
PMID: 41610902